Molecular imaging with radiolabeled anti-PD-L1 antibodies comprehensively and dynamically assesses tumor PD-L1 expression in vivo, and monitors the possible changes in tumor PD-L1 expression during treatment. The gene discussed is CD274; the disease is neoplasm.